Clene (CLNN) just unveiled an update.
Clene Inc. made a significant announcement on June 17, 2024, at the ENCALS Meeting, presenting promising clinical results of their CNM-Au8® treatment in an ongoing ALS trial. The next day, the company further publicized the extended survival data and new findings regarding neurofilament light responder results from the same trial, reinforcing the potential impact of their treatment on ALS patients, and sparking interest among investors and the wider public eyeing advancements in medical treatments.
For an in-depth examination of CLNN stock, go to TipRanks’ Stock Analysis page.